• Login
    View Item 
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Coronavirus Publications
    • View Item
    •   UMB Digital Archive
    • UMB Open Access Articles
    • UMB Coronavirus Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UMB Digital ArchiveCommunitiesPublication DateAuthorsTitlesSubjectsThis CollectionPublication DateAuthorsTitlesSubjects

    My Account

    LoginRegister

    Statistics

    Display statistics

    Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Publisher version
    View Source
    Access full-text PDFOpen Access
    View Source
    Check access options
    Check access options
    Author
    Coleman, C.M.
    Taylor, J.K.
    Frieman, M.B.
    Date
    2014
    Journal
    Vaccine
    Publisher
    Elsevier Ltd
    Type
    Article
    
    Metadata
    Show full item record
    See at
    https://doi.org/10.1016/j.vaccine.2014.04.016
    Abstract
    Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame.The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells.Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.
    Sponsors
    This project has been funded in part by a supplement to NIH RO1 AI095569.
    Keyword
    Middle East Respiratory Syndrome Coronavirus
    Neutralizing antibody
    Severe Acute Respiratory Syndrome Coronavirus
    Vaccine
    MERS-CoV
    SARS-CoV
    SARS Virus
    Identifier to cite or link to this item
    https://www.scopus.com/inward/record.uri?eid=2-s2.0-84900416594&doi=10.1016%2fj.vaccine.2014.04.016&partnerID=40&md5=5ce359dd4124453063200af4939f4550; http://hdl.handle.net/10713/12418
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.vaccine.2014.04.016
    Scopus Count
    Collections
    UMB Coronavirus Publications

    entitlement

    Related articles

    • Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
    • Authors: Tai W, Wang Y, Fett CA, Zhao G, Li F, Perlman S, Jiang S, Zhou Y, Du L
    • Issue date: 2017 Jan 1
    • MERS-CoV spike nanoparticles protect mice from MERS-CoV infection.
    • Authors: Coleman CM, Venkataraman T, Liu YV, Glenn GM, Smith GE, Flyer DC, Frieman MB
    • Issue date: 2017 Mar 14
    • A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
    • Authors: Malczyk AH, Kupke A, Prüfer S, Scheuplein VA, Hutzler S, Kreuz D, Beissert T, Bauer S, Hubich-Rau S, Tondera C, Eldin HS, Schmidt J, Vergara-Alert J, Süzer Y, Seifried J, Hanschmann KM, Kalinke U, Herold S, Sahin U, Cichutek K, Waibler Z, Eickmann M, Becker S, Mühlebach MD
    • Issue date: 2015 Nov
    • Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
    • Authors: Choi JA, Goo J, Yang E, Jung DI, Lee S, Rho S, Jeong Y, Park YS, Park H, Moon YH, Park U, Seo SH, Lee H, Lee JM, Cho NH, Song M, Kim JO
    • Issue date: 2020 Nov 23
    • Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice.
    • Authors: Kim E, Okada K, Kenniston T, Raj VS, AlHajri MM, Farag EA, AlHajri F, Osterhaus AD, Haagmans BL, Gambotto A
    • Issue date: 2014 Oct 14
    DSpace software (copyright © 2002 - 2021)  DuraSpace
    Quick Guide | Policies | Contact Us | UMB Health Sciences & Human Services Library
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.